Federal Right to Try 2.0-The Wrong Approach for Investigational Individualized Treatments.

Right to Try 2.0 fails to address key issues in providing investigational individualized treatments, risking patient safety and treatment efficacy.

• Why it matters: Expanding access to experimental treatments without sufficient oversight can lead to harm and undermine clinical standards, highlighting the need for careful regulation.
• What they did: The viewpoint critiques the Right to Try 2.0 by analyzing its approach to individualized treatments and the potential consequences of its implementation.
• The result: The analysis suggests that the current approach may compromise patient safety and treatment quality, emphasizing the importance of more rigorous oversight and regulation.